SLE (SYSTEMIC LUPUS)
Clinical trials for SLE (SYSTEMIC LUPUS) explained in plain language.
Never miss a new study
Get alerted when new SLE (SYSTEMIC LUPUS) trials appear
Sign up with your email to follow new studies for SLE (SYSTEMIC LUPUS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment using specially engineered immune cells (CAR-T) to target and calm overactive immune cells in people with autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. About 20 adults aged 18 to 70 with active disease will receive either CD…
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 05:43 UTC
-
New lupus drug trial aims to tame immune system
Disease control Recruiting nowThis early-stage study tests a new drug, CLN-978, in 24 people with moderate to severe lupus. The goal is to see if it is safe and can help control the disease by reducing certain immune cells. Participants receive the drug as a shot under the skin.
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated May 17, 2026 05:33 UTC
-
New hope for lupus skin flares: experimental drug VENT-03 enters Mid-Stage trial
Disease control Recruiting nowThis study tests whether an experimental drug called VENT-03 can reduce skin symptoms in people with cutaneous lupus (CLE), with or without systemic lupus (SLE). About 24 adults will receive either VENT-03 or a placebo for 4 weeks, then all will receive VENT-03 for 8 more weeks. …
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE2 • Sponsor: Ventus Therapeutics U.S., Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Engineered cells take aim at tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new treatment called CTX112 for people with severe autoimmune diseases like lupus, scleroderma, or myositis that haven't improved with standard therapies. CTX112 uses specially engineered immune cells from a donor to target and attack faulty immune …
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug trial aims to tame autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug, SAR448501/DR-0201, in 62 adults with lupus or rheumatoid arthritis. The goal is to find the safest and most effective dose by checking side effects and how the drug works in the body. Participants will be followed for about 13 months, and …
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated May 04, 2026 16:24 UTC